Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in moderate-to-severe ulcerative colitis after biologic failure
NCT03482635Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of spesolimab in ulcerative colitis (UC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Clinical Remission at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
spesolimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03482635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482635.